培美曲赛联合奈达铂治疗晚期肺腺癌的临床观察.docVIP

精品论文 参考文献 培美曲赛联合奈达铂治疗晚期肺腺癌的临床观察 徐珊琦 张明辉 刘静蕾 赵红丽 王艳(通讯作者) （哈尔滨医科大学附属肿瘤医院内五科 150081） 【摘要】目的 探讨培美曲赛联合奈达铂治疗晚期肺腺癌的疗效及毒副作用。方法　收集48例经病理组织学或细胞学确诊的晚期肺腺癌患者，接受培美曲赛联合奈达铂方案化疗：培美曲赛 500mg/㎡ d1 静点，奈达铂 85mg/㎡，d2或d2-5静点。每例患者均治疗2周期以上，观察疗效及毒副反应。结果　48例患者均可评价疗效，获得PR 11例，SD 19例，PD18例，有效率为22.9%（11/48），疾病控制率为62.5%(30/48)，中位无进展生存期为10.3个月，主要毒副作用包括骨髓抑制、胃肠道反应、乏力和周围神经毒性，以I-II度为主。结论　培美曲赛联合奈达铂方案治疗晚期肺腺癌疗效确切，毒副反应发生率较低，耐受性好。 【关键词】培美曲赛 奈达铂 肺腺癌 【中图分类号】R453 【文献标识码】A 【文章编号】2095-1752（2013）23-0126-02 Pemetrexed combined with nedaplatin in treatment of patients with adcanced lung adenocacinoma 【Abstract】 Objective: To observe the efficacy and adverse reaction of pemetrexed combined with nedaplatin in the treatment of patients with advanced lung adenocarcinoma. Methods:48 advanced stage adenocarcinoma patients were finally confirmed by pathohistological or cytological examination.500mg/㎡Pemetrexed was mixed with 100ml normal saline which was then dripped IV on the first day; And 85mg/㎡Nedaplatin was mixed with 500 ml normal saline which was then dripped IV on the second or second to fifth day，with 21 day being a cycle. The efficacy and toxic reaction were evaluated after at least 2 cycles. Results: All the 48 patients had completed a total of 142 treatment cycles，the efficacy evaluation could be conducted in everyone of them，in which there were 11 cases of PR，19 cases of SD，and 18 cases of PD，while the objective response rate(RR)reached 22.9%(11/48），the disease control rate(DCR) reached 62.5%(30/48)，and the PFS was 10.3 months.Major adverse effects were myelosuppression，lassitude and gastrointestinal tract reactions，most of which were I-II degree degree.Conclusion: Pemetrexed combination with Nedaplatin provide advanced lung adenocarcinoma patients with good curative effect, quality of life, and adverse effect are tolerable. 【Keywords】 Pemetrexed Nedaplatin Lung adenocacinoma 非小细胞肺癌（NSCLC）早期诊断存在一定困难，许多患者确诊时已为中晚期，失去手术机会。由于难以早期诊断，86%的